##医药集采再现串标丑闻，六家企业被列入“违规名单”
**中新社北京8月21日电** 国家医疗保障局21日发布通报，严厉打击药品集采中的串通投标行为，六家企业因在第七批国家组织药品集中采购中涉嫌串标被列入“违规名单”，并被暂停一定期限内参与国家组织药品集中采购的资格。
通报指出，经查，盐酸溴己新注射液的六家投标企业，包括成都欣捷高新技术开发股份有限公司、仁合益康集团有限公司等，以及占某泽、黄某栋等自然人团伙成员和部分代理商，通过签订代理协议、协商申报价格、利益分成等方式，事先约定了中选企业和落选企业，涉嫌违反采购标书及有关法律规定，并造成医保基金损失。
国家医保局已将相关企业串通投标造成的多支出的资金追回至医保基金，并取消了四家原中选企业的资格。各省份医药集中采购机构已分别对参与串通投标的企业实施“严重”等级的失信评级，有关企业的盐酸溴己新注射液挂网资格、企业参与集中采购的申报资格或入围顺位、综合评分等将受到不同程度约束。此外，各有关部门已对串通投标团伙、六家企业及有关人员涉嫌违法犯罪问题开展调查。
国家组织药品集中采购是重大惠民政策，旨在降低药品价格，减轻患者负担。此次事件再次暴露出医药购销领域存在着一些企业和个人为了自身利益，不惜铤而走险，损害国家利益和人民利益的现象。
国家医保局表示，将持续积极防范、坚决打击医药采购中的违法犯罪行为，为医药集采营造良好的法治环境。同时，也呼吁社会各界共同关注、监督医药集中采购工作，维护公平竞争的市场秩序。
**专家分析**
业内专家指出，此次事件再次警示医药企业，串通投标等违法行为不仅会损害医保基金，更会严重损害企业声誉和利益，最终将受到法律的严惩。医药企业应加强自身合规建设，规范参与医药集中采购，维护公平竞争的市场环境，共同推动医药行业健康发展。
**社会反响**
此次事件引发社会广泛关注，网友纷纷表示对串标行为的愤慨，并呼吁相关部门加大打击力度，维护医药集采的公平公正。一些网友还建议建立完善的监管机制，加强对医药企业和人员的诚信体系建设，杜绝此类事件再次发生。
**未来展望**
国家医保局表示，将继续完善医药集采制度，加强监管力度，坚决打击串标等违法行为，为患者提供更加安全、有效的药品，维护人民群众的切身利益。相信随着制度的不断完善和监管的不断加强，医药集采将更加规范，更加透明，更好地服务于人民健康。
英语如下：
##Drug Procurement Scandal Exposed: Cartel Bid-Rigging Severely Punished
**Keywords:** Procurement violations, bid-rigging, severe punishment
##Bid-rigging Scandal Resurfaces in Pharmaceutical Procurement, Six Companies Blacklisted
**BEIJING, Aug. 21 (CNS)** – TheNational Healthcare Security Administration (NHSA) issued a statement on Monday, vowing to crack down on bid-rigging in pharmaceutical procurement. Six companies were blacklisted for their alleged involvement in bid-rigging during the seventh round of national centralized drug procurement. They were suspended from participating in future national drug procurement programs for a specified period.
The statement revealed that six bidders for Bromhexine Hydrochloride Injection, including Chengdu Xinjie High-tech Development Co., Ltd., Renhe Yikang Group Co., Ltd., and individuals like Zhan Mouze and Huang Moudong, along with some agents, had colluded to pre-determinewinning and losing bidders. They allegedly violated procurement specifications and relevant laws through signing agency agreements, negotiating bid prices, and sharing profits. This resulted in losses to the medical insurance fund.
The NHSA has recovered the excess funds caused by bid-rigging from the companies and revoked the qualification of four original winning bidders.Provincial pharmaceutical procurement agencies have assigned a “serious” level of credit rating to the companies involved in bid-rigging. Their listing qualifications for Bromhexine Hydrochloride Injection, participation in centralized procurement, bid qualification, and comprehensive scoring will be subject to varying degrees of restrictions. Additionally, relevant departments have launched investigations into thebid-rigging cartel, the six companies, and individuals involved for potential criminal offenses.
National centralized drug procurement is a major policy for public benefit, aiming to lower drug prices and alleviate patient burdens. This incident exposes the existence of companies and individuals in the pharmaceutical procurement sector who, driven by self-interest, resortto illegal acts that harm national and public interests.
The NHSA stated that it will continue to actively prevent and resolutely crack down on illegal activities in pharmaceutical procurement, creating a sound legal environment for drug procurement. It also called on the public to actively participate in monitoring pharmaceutical procurement and maintaining a fair and competitive market order.
**Expert Analysis**
Industry experts pointed out that this incident serves as a warning to pharmaceutical companies that illegal activities like bid-rigging not only damage the medical insurance fund but also severely harm their reputation and interests, ultimately leading to legal consequences. Pharmaceutical companies should strengthen their compliance construction, participate in pharmaceutical procurement in astandardized manner, maintain a fair and competitive market environment, and jointly promote the healthy development of the pharmaceutical industry.
**Public Response**
The incident has sparked widespread public concern, with netizens expressing outrage over bid-rigging and calling for stricter enforcement to ensure fairness and justice in pharmaceutical procurement. Some netizens also suggested establishinga sound regulatory mechanism and strengthening the credit system for pharmaceutical companies and personnel to prevent such incidents from recurring.
**Future Outlook**
The NHSA stated that it will continue to improve the pharmaceutical procurement system, strengthen supervision, resolutely crack down on illegal activities like bid-rigging, provide patients with safer and more effectivedrugs, and safeguard the fundamental interests of the people. It is believed that with continuous system improvement and strengthened supervision, pharmaceutical procurement will become more standardized and transparent, better serving the health of the people.
【来源】http://www.chinanews.com/sh/2024/08-21/10272599.shtml
Views: 2